Retatrutide beats Ozempic on weight loss, blood sugar control, study says
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Retatrutide beats Ozempic on weight loss, blood sugar control, study says" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include KHOU and WXLV. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 19m ago.
Quick answers
Why is "Retatrutide beats Ozempic on weight loss, blood sugar control, study says" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial PR Newswire · 8h ago
- Eli Lilly says retatrutide shows more weight loss compared to Ozempic KHOU · 8h ago
- Experimental Lilly drug tops Ozempic in weight loss study WXLV · 8h ago
Topics
Related trends
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
Someone Ran a Chemical Analysis of Bodega Retatrutide and Dear Lord
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials
An investigational triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in late-stage clinical trials.
Tests of Unapproved Weight- Loss Drug Reveal Its Dangers
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
15% Of Americans Have Taken A GLP-1, And Dermatologists Now Have A Timeline For When The Hair Goes
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
Patient-Reported Changes in Alcohol Use Following GLP-1 RA Initiation
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.